Denali Therapeutics announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ETV:IDS (DNL310) for the treatment of patients with Hunter syndrome (MPS II).
Denali Therapeutics,?launched?in May 2015 by three former?Genentech?researchers, just went?public,?raising?$250 million with shares priced at $18. It is trading under the ticker DNLI.